Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Malignant Lymphoma

Free Subscription 01.01.2020 1 Am J Clin Pathol 8 Am J Hematol 10 Blood 3 BMC Cancer 5 Br J Haematol 2 Cancer 1 Cancer Lett 1 Eur J Haematol 2 Haematologica 1 J Clin Oncol 2 Lancet Oncol 4 Leuk Lymphoma 1 Mod Pathol 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Pathol

1. QAYYUM S, Bullock GC, Swerdlow SH, Brower R, et al
   Diagnostic Utility of Isolated Tube C Positivity in T-Cell Receptor beta Testing Using BIOMED-2 Primers.
   Am J Clin Pathol. 2019;151:386-394.
   PubMed     Text format     Abstract available
   
   

   
   Am J Hematol

2. FURUTANI E, Newburger PE, Shimamura A
   Neutropenia in the age of genetic testing: Advances and challenges.
   Am J Hematol. 2019;94:384-393.
   PubMed     Text format     Abstract available
   
   
3. HAMLIN PA, Flinn IW, Wagner-Johnston N, Burger JA, et al
   Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
   Am J Hematol. 2019;94:E90-E93.
   PubMed     Text format    
   
   
4. SMITH SD, Reddy P, Sokolova A, Chow VA, et al
   Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.
   Am J Hematol. 2019;94:E117-E116.
   PubMed     Text format    
   
   
5. ISIDORI A, Loscocco F, Guiducci B, Visani G, et al
   Benda-EAM prior to ASCT and renal toxicity: Much ado about nothing.
   Am J Hematol. 2019;94:E104-E105.
   PubMed     Text format    
   
   
6. PARSONS K, Leach M, Bain BJ
   Hodgkin lymphoma in a bone marrow aspirate.
   Am J Hematol. 2019 Dec 17. doi: 10.1002/ajh.25708.
   PubMed     Text format    
   
   
7. OLSZEWSKI AJ, Butera JN, Reagan JL, Castillo JJ, et al
   Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
   Am J Hematol. 2019 Dec 17. doi: 10.1002/ajh.25707.
   PubMed     Text format     Abstract available
   
   
8. DREYLING M, Santoro A, Mollica L, Leppa S, et al
   Long-term safety and efficacy of the PI3K- inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
   Am J Hematol. 2019 Dec 23. doi: 10.1002/ajh.25711.
   PubMed     Text format     Abstract available
   
   
9. CHANTEPIE S, Yakoub-Agha I, Damaj G
   Be ever cautious until the truth is proven.
   Am J Hematol. 2019;94:E106.
   PubMed     Text format    
   
   

   
   Blood

10. ZHAN Y, Teruya-Feldstein J
    Immune dysregulation: EBV(+) DLBCL and HLH in a patient with T-LGL.
    Blood. 2019;133:1695.
    PubMed     Text format    
    
    
11. NEELAPU SS
    CAR-T efficacy: is conditioning the key?
    Blood. 2019;133:1799-1800.
    PubMed     Text format    
    
    
12. PASCUAL M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, et al
    PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
    Blood. 2019;133:2401-2412.
    PubMed     Text format     Abstract available
    
    
13. FORERO-TORRES A, Ramchandren R, Yacoub A, Wertheim MS, et al
    Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies.
    Blood. 2019;133:1742-1752.
    PubMed     Text format     Abstract available
    
    
14. WILLEMZE R, Cerroni L, Kempf W, Berti E, et al
    The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.
    Blood. 2019;133:1703-1714.
    PubMed     Text format     Abstract available
    
    
15. HERBAUX C, Davids MS
    Venetoclax: R-CHOP rocket booster?
    Blood. 2019;133:1922-1924.
    PubMed     Text format    
    
    
16. CONNORS JM
    To treat or not to treat, that is the NLPHL question.
    Blood. 2019;133:2113-2114.
    PubMed     Text format    
    
    
17. RUMI E, Zibellini S
    JAK inhibitors and risk of B-cell lymphomas.
    Blood. 2019;133:2251-2253.
    PubMed     Text format    
    
    
18. MARTINO G, Ascani S
    Seronegative visceral leishmaniasis with bone marrow and hepatic involvement.
    Blood. 2019;133:2353.
    PubMed     Text format    
    
    
19. KARMALI R, Gordon LI
    Revving up the immune engine in cHL.
    Blood. 2019;134:1-2.
    PubMed     Text format    
    
    

    
    BMC Cancer

20. APPLEBY N, Eyre TA, Cabes M, Jackson A, et al
    The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agent
    BMC Cancer. 2019;19:471.
    PubMed     Text format     Abstract available
    
    
21. CATALANI S, Donato F, Madeo E, Apostoli P, et al
    Occupational exposure to formaldehyde and risk of non hodgkin lymphoma: a meta-analysis.
    BMC Cancer. 2019;19:1245.
    PubMed     Text format     Abstract available
    
    
22. KOFFI KG, Silue DA, Laurent C, Boidy K, et al
    AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study.
    BMC Cancer. 2019;19:1247.
    PubMed     Text format     Abstract available
    
    

    
    Br J Haematol

23. RAIMBAULT A, Machherndl-Spandl S, Itzykson R, Clauser S, et al
    CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.
    Br J Haematol. 2019;184:625-633.
    PubMed     Text format     Abstract available
    
    
24. RODGERS TD, Baran A, Reagan PM, Casulo C, et al
    Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Dec 17. doi: 10.1111/bjh.16302.
    PubMed     Text format    
    
    
25. PETTENGELL R, Dlugosz-Danecka M, Andorsky D, Belada D, et al
    Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).
    Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16255.
    PubMed     Text format     Abstract available
    
    
26. DUFFLES AMARANTE G, Collins G, Rocha V
    What do we know about duodenal-type follicular lymphoma? From pathological definition to treatment options.
    Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16348.
    PubMed     Text format     Abstract available
    
    
27. SORGE C, Costa LJ, Taub JW, S Cairo M, et al
    Incidence and outcomes of rare paediatric non-hodgkin lymphomas.
    Br J Haematol. 2019;184:864-867.
    PubMed     Text format    
    
    

    
    Cancer

28. KANAGAL-SHAMANNA R, Jain P, Patel KP, Routbort M, et al
    Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Cancer. 2018 Dec 3. doi: 10.1002/cncr.31831.
    PubMed     Text format     Abstract available
    
    
29. CHANDRASEKAR T, Goldberg H, Klaassen Z, Wallis CJD, et al
    The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity.
    Cancer. 2019;125:1050-1059.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

30. LABI V, Schoeler K, Melamed D
    miR-17 approximately 92 in lymphocyte development and lymphomagenesis.
    Cancer Lett. 2019;446:73-80.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Haematol

31. SINDEL A, Taylor T, Chesney A, Clark W, et al
    Hematopoietic stem cell mobilization following PD-1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid.
    Eur J Haematol. 2019;103:134-136.
    PubMed     Text format     Abstract available
    
    

    
    Haematologica

32. CHAMULEAU MED, Burggraaff CN, Nijland M, Bakunina K, et al
    Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
    Haematologica. 2019 Dec 19. pii: haematol.2019.238162.
    PubMed     Text format     Abstract available
    
    
33. MARSCHALEK R
    Another piece of the puzzle added to understand t(4;11) leukemia better.
    Haematologica. 2019;104:1098-1100.
    PubMed     Text format    
    
    

    
    J Clin Oncol

34. SHI Q, Flowers CR
    Reply to H.J.A. Adams et al.
    J Clin Oncol. 2019;37:526-527.
    PubMed     Text format    
    
    

    
    Lancet Oncol

35. LIN GW, Xu C, Chen K, Huang HQ, et al
    Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.
    Lancet Oncol. 2019 Dec 23. pii: S1470-2045(19)30799.
    PubMed     Text format     Abstract available
    
    
36. KUCUK C
    Genetic susceptibility to natural killer T-cell lymphoma.
    Lancet Oncol. 2019 Dec 23. pii: S1470-2045(19)30820.
    PubMed     Text format    
    
    

    
    Leuk Lymphoma

37. JALALI S, Ansell SM
    The potential role of glycogen metabolism in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Dec 17:1-9. doi: 10.1080/10428194.2019.1702185.
    PubMed     Text format     Abstract available
    
    
38. LIPSCOMB J, Switchenko JM, Flowers CR, Gillespie TW, et al
    Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia.
    Leuk Lymphoma. 2019 Dec 18:1-9. doi: 10.1080/10428194.2019.1702176.
    PubMed     Text format     Abstract available
    
    
39. HSU YT, Wang YC, Chen RY, Hung LY, et al
    Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype.
    Leuk Lymphoma. 2019 Dec 23:1-11. doi: 10.1080/10428194.2019.1702179.
    PubMed     Text format     Abstract available
    
    
40. TAKAHASHI T, Ichikawa S, Ichinohasama R, Harigae H, et al
    BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with t(9;22);BCR-ABL1?
    Leuk Lymphoma. 2019 Dec 26:1-3. doi: 10.1080/10428194.2019.1706736.
    PubMed     Text format    
    
    

    
    Mod Pathol

41. OK CY, Medeiros LJ, Thakral B, Tang G, et al
    High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma.
    Mod Pathol. 2019;32:48-58.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

42. BEAUD H, Albert O, Robaire B, Rousseau MC, et al
    Sperm DNA integrity in adult survivors of paediatric leukemia and lymphoma: A pilot study on the impact of age and type of treatment.
    PLoS One. 2019;14:e0226262.
    PubMed     Text format     Abstract available
    
    
43. ZHANG L, Hemminki O, Chen T, Yu H, et al
    Second cancers and causes of death in patients with testicular cancer in Sweden.
    PLoS One. 2019;14:e0214410.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: